Prostate Cancer
Conditions
Keywords
223-Radium-dicloride, Radical prostatectomy, overall survival
Brief summary
The investigators provided a multicenter analysis aiming to investigate, in a clinical practice setting, the prognostic relevance of previous primary radical prostatectomy (RP) or external beam radiotherapy (RT) in terms of Overall Survival as opposed to patients with no primary treatment performed, in a cohort of patients enrolled in 223-Ra treatment for mCRPC. 223-Ra has been administered from investigators according to the current label authorization and all patients underwent 223-Ra treatment, until disease progression or unacceptable toxicity.
Interventions
OTHERRadium223
55 kBq/ Kg
Sponsors
University of Bari Aldo Moro
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
University of Bologna
Università degli Studi di Sassari
Ospedale Civile Spirito Santo
Azienda Policlinico Umberto I
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* histological confirmation of prostatic adenocarcinoma, at least two symptomatic bone secondary lesions detected by bone scan and no known visceral metastases, except for malignant lymphadenopathy with less than 3 cm in the short axis diameter
Exclusion criteria
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score \>2 and inadequate hematological, hepatic and renal function
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of overal survivall | From date of first 223Ra administration until the date of death from any cause or the date of the first documented progression disease, assessed up to 48 months | The survival function, possibly stratified by categorical covariates of interest, was computed using the Kaplan-Meier product-limit estimator. |
Countries
Italy
Contacts
Primary ContactGiuseppe De Vincentis, MD, PhD
Backup ContactVIVIANA FRANTELLIZZI, MD
Outcome results
None listed